Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Severe diabetic retinopathy poses increased cognitive impairment hazard

Jairia Dela Cruz
01 Nov 2019

Patients with moderate or worse diabetic retinopathy (DR) are at much higher odds of developing cognitive impairment, according to a Singapore study.

“Importantly, these findings were independent of key risk factors of cognitive impairment, such as duration of diabetes, HbA1c, education, refractive error, cardiovascular disease (CVD) and visual acuity,” the investigators said.

The study included 682 diabetic participants (mean age, 67.3 years; 44.4 percent female; 30.4 percent Chinese) from the Singapore Epidemiology of Eye Disease Study. DR was present in 199 participants (29.2 percent), among whom 142 (20.8 percent) had minimal/mild disease and 57 (8.4 percent) had moderate or worse disease.

Over the 6-year follow-up, 40 participants (5.9 percent) were found to have cognitive impairment based on Abbreviated Mental Test screening, corresponding to an incidence rate of 5.9 percent. This group of individuals was older, more likely to be female, of Indian ethnicity, had lower education and poorer presenting distance visual acuity (p-all<0.05). [Br J Ophthalmol 2019;103:1605-1609]

In multivariate analysis regression models, participants with any DR were more than twice as likely as those without the diabetic eye disease to have cognitive impairment (odds ratio [OR], 2.32, 95 percent CI, 1.07–5.03). The odds were threefold higher in participants with moderate or worse DR (OR, 3.41, 1.06–11.00).

“Although these results need to be interpreted with caution due to the small number of individuals with incident CI, the data suggest that the significant diabetes–cognitive impairment relationship observed in previous studies may have been driven by the presence of diabetic microvascular complications in these individuals,” according to the investigators, stressing that larger cohort studies are needed to verify the present data and establish underlying mechanisms.

Given that retinal and cerebral small vessels share similar embryological origin, size, structure and physiological characteristics, including the blood-brain and blood-retinal barrier, the investigators speculate that retinal abnormalities in DR may also signal abnormalities within the blood-brain barrier, leading to cognitive decline. [J Anat 2005;206:319-348]

“Our findings highlight the importance of systematic preventative strategies such as regular eye screening, to prevent and slow DR progression, notably advanced DR,” the investigators said.

Clinicians managing patients with DR should therefore consider incorporating cognitive impairment monitoring and treatment, which in turn can improve the quality of life in both patients and their caregivers, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.